AU2002216095B2 - Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists - Google Patents

Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists Download PDF

Info

Publication number
AU2002216095B2
AU2002216095B2 AU2002216095A AU2002216095A AU2002216095B2 AU 2002216095 B2 AU2002216095 B2 AU 2002216095B2 AU 2002216095 A AU2002216095 A AU 2002216095A AU 2002216095 A AU2002216095 A AU 2002216095A AU 2002216095 B2 AU2002216095 B2 AU 2002216095B2
Authority
AU
Australia
Prior art keywords
group
compound
formula
lower alkyl
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002216095A
Other languages
English (en)
Other versions
AU2002216095A1 (en
Inventor
Alfred Binggeli
Hans-Peter Maerki
Vincent Mutel
Maurice Wilhelm
Wolfgang Wostl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2002216095A1 publication Critical patent/AU2002216095A1/en
Application granted granted Critical
Publication of AU2002216095B2 publication Critical patent/AU2002216095B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2002216095A 2000-12-22 2001-12-11 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists Ceased AU2002216095B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00128329.0 2000-12-22
EP00128329 2000-12-22
PCT/EP2001/014527 WO2002051418A1 (en) 2000-12-22 2001-12-11 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists

Publications (2)

Publication Number Publication Date
AU2002216095A1 AU2002216095A1 (en) 2003-01-23
AU2002216095B2 true AU2002216095B2 (en) 2005-12-01

Family

ID=8170787

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002216095A Ceased AU2002216095B2 (en) 2000-12-22 2001-12-11 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists

Country Status (17)

Country Link
US (1) US6586422B2 (enExample)
EP (1) EP1345609B1 (enExample)
JP (1) JP4077319B2 (enExample)
KR (1) KR100545906B1 (enExample)
CN (1) CN1260226C (enExample)
AR (1) AR032379A1 (enExample)
AT (1) ATE297734T1 (enExample)
AU (1) AU2002216095B2 (enExample)
BR (1) BR0116378A (enExample)
CA (1) CA2432077C (enExample)
DE (1) DE60111568T2 (enExample)
DK (1) DK1345609T3 (enExample)
ES (1) ES2243400T3 (enExample)
MX (1) MXPA03005515A (enExample)
PT (1) PT1345609E (enExample)
WO (1) WO2002051418A1 (enExample)
ZA (1) ZA200304557B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1981337B1 (en) * 2006-01-19 2015-09-02 Athersys, Inc. Thiophenyl azepines as serotonin 5-ht2c receptor ligands and uses thereof
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101100864B1 (ko) * 2009-06-12 2012-01-02 양준호 자동차 광택기용 광택패드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3136654A1 (de) 1981-09-16 1983-03-31 Zahnradfabrik Friedrichshafen Ag, 7990 Friedrichshafen Linearverschieblicher arbeitsarm, insbesondere fuer handhabungsgeraete
WO1999044639A1 (en) * 1998-03-03 1999-09-10 Yamanouchi Pharmaceutical Co., Ltd. Remedies for brain infarction
ID29095A (id) * 1998-10-02 2001-07-26 Novartis Ag Cs Antagonis mglur5 untuk pengobatan rasa sakit dan kegelisahan
GB9823847D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
ES2209728T3 (es) * 1999-08-06 2004-07-01 F. Hoffmann-La Roche Ag Tetrahidro-benzo(d)azepinas y su uso como antagonistas de receptores de glutamato metabotropico.
EP1074549B1 (en) * 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors

Also Published As

Publication number Publication date
PT1345609E (pt) 2005-08-31
ZA200304557B (en) 2004-09-13
ES2243400T3 (es) 2005-12-01
CN1487831A (zh) 2004-04-07
EP1345609B1 (en) 2005-06-15
US6586422B2 (en) 2003-07-01
CA2432077C (en) 2011-01-18
CN1260226C (zh) 2006-06-21
MXPA03005515A (es) 2003-09-25
JP4077319B2 (ja) 2008-04-16
AR032379A1 (es) 2003-11-05
US20020123488A1 (en) 2002-09-05
KR100545906B1 (ko) 2006-01-26
CA2432077A1 (en) 2002-07-04
ATE297734T1 (de) 2005-07-15
KR20030062444A (ko) 2003-07-25
WO2002051418A1 (en) 2002-07-04
BR0116378A (pt) 2003-10-28
DE60111568T2 (de) 2006-05-11
DE60111568D1 (de) 2005-07-21
DK1345609T3 (da) 2005-10-03
EP1345609A1 (en) 2003-09-24
JP2004517850A (ja) 2004-06-17

Similar Documents

Publication Publication Date Title
EP1303521B1 (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives
US7176195B2 (en) Fused azepine derivatives and their use as antidiuretic agents
AU2002210418A1 (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives
CZ20031311A3 (cs) Deriváty tetrahydroazepinu, užitečné jako modulátory receptorů dopaminu D3 (antipsychotická činidla)
US20100190772A1 (en) Substituted Azepine Derivatives As Serotonin Receptor Modulators
US6586422B2 (en) Pyrazine and triazine derivatives of 1,2,4,5-tetrahydro-Benzo or Thieno [d] azepine
ES2294504T3 (es) Derivados de imidazol como antagonistas de receptor de glutamato.
AU2002216095A1 (en) Tetrahydro-(Benzo or Thieno)-Azepine-Pyrazine and Triazine Derivatives as mGluR 1 Antagonists
WO1997003986A1 (en) Fused triazole compounds
MXPA00003390A (es) Derivado de tiazolbenzoimidazol novedoso.
AU2014289398B2 (en) Ethynyl derivatives as metabotropic glutamate receptor antagonists
CZ290678B6 (cs) 3-Substituované 3,4,5,7-tetrahydropyrrolo[3´,4´: 4,5]thieno[2,3-d]pyrimidinové deriváty, způsob jejich přípravy a použití
CN100562520C (zh) 咪唑衍生物ⅲ
AU748697B2 (en) 3-substituted pyrido {3',4':4,5} thieno {2,3-D} pyrimidine derivatives, and production and use of the same
NL8503426A (nl) 8alfa-acylamino-ergolinen, werkwijzen voor hun bereiding en farmaceutische preparaten die ze bevatten.
JPWO1997003986A1 (ja) 縮合トリアゾール化合物
IT8448448A1 (it) Composti tetraciclici capaci di modificare l'umore, composizioni che li contengono e procedimento per prepararli ed applicarli

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired